Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other Accumulated Expenses (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Other Accumulated Expenses for 16 consecutive years, with $1.3 million as the latest value for Q2 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $1.3 million in Q2 2025 year-over-year; TTM through Jun 2025 was $1.3 million, a N/A change, with the full-year FY2024 number at $1.2 million, changed 0.48% from a year prior.
  • Other Accumulated Expenses was $1.3 million for Q2 2025 at Harvard Bioscience, up from $1.2 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $7.8 million in Q2 2021 to a low of $956000.0 in Q3 2022.
  • A 5-year average of $2.5 million and a median of $1.3 million in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 397.41% in 2022, then crashed 83.44% in 2023.
  • Harvard Bioscience's Other Accumulated Expenses stood at $1.5 million in 2021, then soared by 397.41% to $7.5 million in 2022, then crashed by 83.44% to $1.2 million in 2023, then dropped by 0.48% to $1.2 million in 2024, then rose by 3.48% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Other Accumulated Expenses are $1.3 million (Q2 2025), $1.2 million (Q4 2024), and $1.5 million (Q1 2024).